What are the differences between ependymoma, schwannoma (Schwann cell tumor), and meningioma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differentiation Between Ependymoma, Schwannoma, and Meningioma

Ependymoma, schwannoma, and meningioma are distinct CNS tumors with characteristic clinical, radiological, and histopathological features that guide their diagnosis and management.

Origin and Location

Ependymoma

  • Origin: Neuroectodermal origin, arising from ependymal cells lining the ventricular system 1
  • Location: Primarily intraventricular or paraventricular; commonly found in the fourth ventricle in children and spinal cord in adults 1
  • Distribution: Account for 1.8% of all primary CNS tumors and 6.8% of all gliomas 1

Schwannoma

  • Origin: Arise from Schwann cells of cranial or spinal nerves 2
  • Location: Most commonly vestibular schwannomas (VS) from the eighth cranial nerve; represent 6-8% of all intracranial tumors and 80-94% of cerebellopontine angle tumors 2
  • Association: Strongly associated with neurofibromatosis type 2 (NF2), particularly bilateral vestibular schwannomas 1

Meningioma

  • Origin: Arise from arachnoid cap cells of the meninges 1
  • Location: Attached to the dura mater; can occur anywhere along the dural surface 1
  • Prevalence: Most common primary CNS tumor from age 35 years through old age; more common in women 1

Clinical Presentation

Ependymoma

  • Symptoms depend on location and size
  • Intracranial: Increased intracranial pressure, headache, vomiting
  • Spinal: Back pain, sensory/motor deficits related to spinal cord compression 1

Schwannoma

  • Vestibular schwannomas: Hearing loss (95%), tinnitus (63%), disequilibrium (61%), headache (32%) 2
  • Symptoms primarily due to compression of surrounding structures (cranial nerves, vessels, brainstem) 2

Meningioma

  • Often asymptomatic and discovered incidentally
  • Symptoms depend on location: seizures, focal neurological deficits, headache
  • Generally slow-growing 1

Radiological Features

Ependymoma

  • Intraventricular or paraventricular location
  • Variable enhancement pattern
  • May show "drop metastases" in the spinal canal 1

Schwannoma

  • Well-circumscribed, enhancing masses in cerebellopontine angle or along nerve roots
  • MRI is the gold standard for diagnosis 2
  • Often shows cystic components and heterogeneous enhancement 1

Meningioma

  • Extra-axial, dural-based masses with homogeneous enhancement
  • Often show a "dural tail" sign
  • May demonstrate calcification and hyperostosis of adjacent bone 1

Histopathology

Ependymoma

  • WHO grades I-III (myxopapillary ependymoma is grade I)
  • Characteristic perivascular pseudorosettes and true ependymal rosettes
  • Nine molecular subgroups identified across different anatomical compartments 1
  • Tanycytic ependymoma variant can be mistaken for schwannoma 3

Schwannoma

  • WHO grade I tumors
  • Biphasic pattern with Antoni A (compact) and Antoni B (loose) areas
  • Verocay bodies (palisading nuclei)
  • Strong S-100 protein immunoreactivity 2

Meningioma

  • WHO grades I-III, most are grade I
  • Whorled pattern of meningothelial cells
  • Psammoma bodies (calcified concretions)
  • Often show positive staining for epithelial membrane antigen (EMA) 1

Molecular Characteristics

Ependymoma

  • Distinct DNA methylation profiles and genetic alterations across nine molecular subgroups 1
  • Molecular classification more precise than histology alone in predicting biological behavior 1

Schwannoma

  • NF2 gene mutations with loss of schwannomin/Merlin protein 4
  • Abnormal interaction between hyaluronan and CD44 receptor contributes to tumorigenesis 5

Meningioma

  • NF2 mutations in approximately 60% of sporadic cases 1
  • Multiple meningiomas often associated with NF2 1
  • More common in women, suggesting hormonal influence 1

Treatment Approaches

Ependymoma

  • Primary treatment: Maximal safe surgical resection 1, 6
  • Adjuvant therapy: Radiotherapy recommended for anaplastic (grade III) ependymomas and incompletely resected grade II tumors 1, 6
  • Spinal ependymomas: Gross total resection is curative in most cases; radiotherapy reserved for incomplete resection 1

Schwannoma

  • Management options: Observation ("watch-and-wait"), surgery, or radiotherapy 2
  • Surgical approach: Retrosigmoid suboccipital approach commonly used 2
  • Goal: Preservation of neurological function, especially facial nerve function and hearing 2
  • Recurrence rate: 0.5-5% after microsurgical removal 2

Meningioma

  • Management: Surveillance or surgery depending on growth history and symptoms 1
  • Surgical indications: Significant growth, parenchymal edema, or clinical symptoms 1
  • Radiosurgery: May be helpful for symptomatic growing tumors in difficult locations like cavernous sinus 1

Prognosis

Ependymoma

  • 5-year overall survival: 83.4%
  • 10-year overall survival: 79.1% 1
  • Prognosis depends on tumor location, extent of resection, and molecular subgroup 1

Schwannoma

  • Generally benign with excellent long-term survival
  • Functional outcomes (hearing, facial nerve function) are key determinants of quality of life 2

Meningioma

  • Excellent prognosis for WHO grade I tumors
  • Higher grade tumors have higher recurrence rates and worse outcomes 1

Key Distinguishing Features

  • Ependymoma: Intraventricular location, perivascular pseudorosettes, association with ventricular system
  • Schwannoma: Association with cranial nerves (especially vestibular), S-100 positivity, Antoni A and B areas
  • Meningioma: Dural attachment, whorled pattern, psammoma bodies, female predominance

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Schwannomas of Brain and Spinal Cord.

Advances in experimental medicine and biology, 2023

Research

Tanycytic ependymoma: highlighting challenges in radio-pathological diagnosis.

Indian journal of pathology & microbiology, 2021

Research

Cerebrospinal Fluid Hyaluronan and Neurofibromatosis Type 2.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2018

Guideline

Treatment of Myxopapillary Ependymoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.